KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives

Key Takeaways KRYS expects Q4 Vyjuvek revenues of $106-$107M on a preliminary basis, lifting full-year sales to $388-$389M.KRYS benefited from strong U.S. uptake and expanded Vyjuvek approvals across Europe and Japan.KRYS expects key 2026 catalysts, including top-line data from KB801 and KB803 registrational studies.Krystal Biotech, Inc. (KRYS) expects preliminary unaudited net product revenues of $106-$107 million from lead drug Vyjuvek in the fourth quarter of 2025, bringing full-year 2025 revenue forecas ...